Debiopharm Innovation Fund: the New Name and Investment Strategy of Debiopharm Diagnostics

Change in name reflects new strategy to invest in smart data, therapeutics and diagnostics

Lausanne, Switzerland – March 07, 2017 – Debiopharm Diagnostics SA, the strategic investment fund of Debiopharm Group™ (, announced its new strategy and the change of name to Debiopharm Innovation Fund SA effective today. With the aim of speeding up innovations that radically improve therapeutic development and treatment of patients, the company is broadening its investment scope beyond diagnostics to include smart data and therapeutics.

Debiopharm Innovation Fund’s objective is to make strategic investments related to Debiopharm Group’s areas of interest: oncology and infectious disease. The fund invests in young companies developing smart data, therapeutic, and diagnostic solutions that will have an impact on patients. Typically the fund invests in therapeutic startups at the preclinical stage, in diagnostics at the development stage, and in smart data at the early commercialization stage.

“We are excited to build a bold portfolio of companies that, for example, use the massively increasing volumes of healthcare data and artificial intelligence to create therapeutics or actionable results for clinicians” said Tanja Dowe, Head of Debiopharm Innovation Fund. She continued “our strategic fund’s vision is to provide Debiopharm Group with an insight to the future through investments in innovative companies that change the way we develop drugs and treat patients.”

About Debiopharm Innovation Fund SA
Part of Debiopharm Group™, a Swiss-headquartered global biopharmaceutical group of five companies, Debiopharm Innovation Fund’s mission is to invest in companies developing innovative therapeutics, diagnostics and smart data solutions that change the way we develop drugs and treat patients. Since 2008, the company has invested nearly USD 100 million and led 10 out of the 14 last investment rounds in its portfolio company.
For more information, please visit
We are on Twitter. Follow us @DebiopharmNews at